Chinese Antibody Society的动态

The authors of this new open access article published in Antibody Therapeutics from Just - Evotec Biologics describe a novel, cost-effective and accelerated approach to therapeutic antibody discovery, that couples de novo human antibodies derived in silico with high throughput screening technologies. Just-Evotec Biologics’ platform’s applicability is demonstrated here by the identification of a panel of humanoid antibodies that are effective and with high developability potential. The first and corresponding author is Cristina Moldovan Loomis, Ph.D.. Antibody Therapeutics, the official journal of Chinese Antibody Society, is an international peer-reviewed, open access journal published by Oxford University Press, and is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal. https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics

Antibody Therapeutics (indexed by ESCI, PubMed & Scopus, 2023 CiteScore: 8.7), the official journal of Chinese Antibody Society published by Oxford University Press would like to share a research article entitled “AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains”. The corresponding author is Cristina Moldovan Loomis, Ph.D. from Just - Evotec Biologics. Here, researchers described a novel, cost-effective and accelerated approach to therapeutic antibody discovery, that couples?de novo?human antibodies derived?in silico?with high-throughput screening technologies. The platform’s applicability is demonstrated here by the identification of a panel of humanoid antibodies that are effective and with high developability potential. Click the link for the free access of the full article https://lnkd.in/g2N_82TN We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics

We would like to feature the excellent article published in Antibody Therapeutics with the title of “The process using a synthetic library that generates multiple diverse human single domain antibodies”. Single domain antibodies (sdAbs) possess unique characteristics that make them highly effective for developing complex therapeutics. Scientists from Tavotek Biotherapeutics demonstrated how screening can identify distinct VHO activities that have been used to generate differentiated drug molecules in various bispecific and multispecific antibody formats by using a fully synthetic phage display library to generate single domain antibodies that can bind to disease relevant antigen conformations. The corresponding author is Mark Tornetta from Tavotek Biotherapeutics. Open access to the paper at https://lnkd.in/eDFykmBP Antibody Therapeutics is the official journal of Chinese Antibody Society, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #Antibody #Therapeutics #mAbs #Biopanning

"The Patient Is Waiting" — A Motto That Drives Us Reposting this reminds me of Biocytogen’s mission: bridging preclinical research and human clinical studies with our humanized mouse models. Just as Alloy Therapeutics, Inc.’ GX mice are transforming antibody discovery. With over 2000 strains of engineered mouse including drug targeted humanized mice models for immuno-oncology and autoimmune diseases, our platform eliminates translational barriers, contributing to multiple clinical-stage antibody therapeutics through global partnerships. We share the urgency of unmet medical needs, empowering drug developers to make a difference for patients who are waiting.

With over 200 bispecific antibodies currently in development, key areas of opportunity are beginning to emerge. A promising area of interest lies in drug resistance. Bi- and multispecific antibodies that target two or more pathways may be able to reduce the risk of drug resistance, creating an opportunity to develop more effective therapies later down the line. At evitria, we recognise the potential of bispecific antibodies and offer rapid expression services to researchers looking to unlock their therapy potential. Get in touch to learn more. #Biotech #DrugResistance #BispecificAntibodies #Antibodies

This new open access research article (currently as accepted manuscript) is just published in Antibody Therapeutics (2023 CiteScore: 8.7). The title of this paper is “Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity”. This paper demonstrate that a HER2-targeting eribulin-containing ADC, BB-1701 had potent antitumor activities against multiple HER2-expressing cancers, especially those insensitive to other HER2-targeting ADCs, and had bystander killing effect and induced immunogenic cell death. The corresponding author is Dr. Yuhong Zhou, the co-founder and CSO of Bliss Biopharmaceutical (Hangzhou) Co., Ltd. This ADC drug, BB-1701 was licensed from Bliss Biopharmaceutical to Eisai in May, 2023 (see announcement: https://lnkd.in/g5qC7VQw). ?BB-1701 indeed contains Eisai’s in-house developed payload eribulin. In comparison with HER2-targeting ADCs with DM1 and Dxd payload, eribulin-containing ADC BB-1701demonstrated higher in vitro cytotoxicity in HER2-low cancer cell lines, as shown in this new paper. Open access to this paper at: https://lnkd.in/gUG9Et3p Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Our society’s official journal, Antibody Therapeutics (2023 CiteScore: 8.7), is an international peer-reviewed, open access journal published by Oxford University Press. You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal. https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate

AntibodyPlus?was introduced by the Chinese Antibody Society (CAS) in 2021 to better reflect the overwhelming growth of antibody-based therapeutics.?Antibody Therapeutics (2023 CiteScore: 8.7), the official journal of Chinese Antibody Society published by Oxford University Press would like to highlight selected articles on this topic. The 1st paper we would like to share is entitled “Next generation of multispecific antibody engineering” contributed by Fernando Garces from Gilead Sciences. Multispecific antibodies recognize two or more epitopes located on the same or distinct targets. This added capability through protein design allows these man-made molecules to address unmet medical needs that are no longer possible with single targeting such as with monoclonal antibodies or cytokines alone. Here, researchers reflected on the current state-of-the-art of therapeutic biologics and looked at the building blocks, in terms of proteins, and tools that can be used to build the foundations of such a next-generation workflow. Click the link for the free access of the full text of the article: https://lnkd.in/eXs2qsre We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics #AntibodyPlus

Early in my career of therapeutic antibody discovery I worked at Pfizer and was given a company motto, “The Patient Is Waiting."?I immediately embraced this concept because I chose a career in industry to make a difference in helping patients.?The motto imparts a sense of urgency to that mission, and I have taken this with me to all my subsequent career stops. This week I had the pleasure of speaking about the Alloy ATX-Gx mice at the Antibody Engineering and Therapeutics conference and I was reminded of the motto as I noted that 9 antibodies discovered using Alloy GX mice are currently in the clinic with 3 in phase II trials.?That is despite the mice only becoming available in 2019!?Additionally, there are more than 60 licensed programs?in our partners' hands, indicating dozens of new antibody drugs discovered using GX mice are headed to the clinic. When Errik Anderson started Alloy Therapeutics, Inc., he had the vision of helping patients by democratizing the humanized transgenic mouse technology and getting it into the hands of drug discoverers worldwide.?This vision is working and perfectly matches the urgency of unmet needs. “The Patient Is Waiting!"

Creative Biolabs has upgraded its Antibody-Drug Conjugate (ADC) platform to streamline the development process and enhance targeted drug delivery. The improved platform offers advanced services for antibody selection, linker design, and efficacy evaluation. 'The platform aims to deploy recommended innovations throughout the ADC drug development process to simplify the workflow,' a manager stated. Antibody selection capabilities have been bolstered to identify optimal antigens and engineer monoclonal antibodies with enhanced affinity, specificity, and stability. The company's 'DrugLnk' platform allows for tailored ADC linker design services, enabling the modification of linker aspects to create compatible drug-linker complexes for diverse antigens. 'We can modify nearly all aspects of the linkers, allowing us to manufacture the most suitable complexes,' experts explained. For evaluation stages, Creative Biolabs has introduced new testing methods like in vitro cytotoxicity assays, internalization assays, and 3D cell culture models mimicking the tumor microenvironment. These advancements aim to comprehensively assess the effectiveness and potential side effects of ADCs. 'This platform will continue evolving to meet market demands and push the boundaries of ADC technology,' the company stated. Creative Biolabs #adc #targeteddrugdelivery #antibodydrugs

This week, Dawn Dufield will present remotely on #Hybrid #LCMS during #AIS. For more information, read on… Recently, we have seen the role of #HybridLCMSMS in the analysis of #AntibodyDrugConjugates (#ADC) increase due to the complexity and number of #bioanalytical assays needed to support this modality in the #DrugDevelopment process. Antibody drug conjugates tend to consist of a toxic small molecule payload attached via a linker to an #antibody. The application of these drugs had mainly been in #oncology where their mode of action is for the antibody to attach at the desired target site with subsequent release of the small molecule to combat #TumorCells. Having a therapeutic entity with multiple distinct components means that we need to have analytical methodologies for various components. Recently, we have seen a trend towards the complete ADC analyses being done by LC-MS/MS. https://lnkd.in/g9hd4Ae6